(Q42621232)

English

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 November 2017

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure (English)

1 reference

Europe PubMed Central

3 November 2017

1 reference

based on heuristic

inferred from title

author name string

Harvey B Dubiner

1

1 reference

Europe PubMed Central

3 November 2017

Marla D Sircy

2

1 reference

Europe PubMed Central

3 November 2017

Theresa Landry

3

1 reference

Europe PubMed Central

3 November 2017

Michael V W Bergamini

4

1 reference

Europe PubMed Central

3 November 2017

Lewis H Silver

5

1 reference

Europe PubMed Central

3 November 2017

F Darell Turner

6

1 reference

Europe PubMed Central

3 November 2017

Stella Robertson

7

1 reference

Europe PubMed Central

3 November 2017

Russell M Andrew

8

1 reference

Europe PubMed Central

3 November 2017

Alan Weiner

9

1 reference

Europe PubMed Central

3 November 2017

Johan Przydryga

10

1 reference

Europe PubMed Central

3 November 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

3 November 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

3 November 2017

26

1 reference

Europe PubMed Central

3 November 2017

84-91

1 reference

Europe PubMed Central

3 November 2017

1

1 reference

Europe PubMed Central

3 November 2017

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A 6-month, randomized, double-masked comparison of latanoprost with timolol in patients with open angle glaucoma or ocular hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP : a 3-month clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The significance of the diurnal tension variations in normal and glaucomatous eyes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2804%2990008-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(04)90008-2

1 reference

Europe PubMed Central

3 November 2017

1 reference

Europe PubMed Central

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42621232&oldid=1963287040"